Geun Seog Song

Geun Seog Song

Auto-generated profile, based on publicly available information

Geun Seog Song

Division of Clinical Development, HK Inno.N Corp., Seoul 04551, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Gut and Liver
Verified
Journal Article
Open access
PDF file
SHSungpil Han
Sungpil Han
HCHee Youn Choi
Hee Youn Choi
YKYo Han Kim
Yo Han Kim
SCSeungChan Choi
SeungChan Choi
SKSeokuee Kim
Seokuee Kim
KBKyun-Seop Bae
Kyun-Seop Bae
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, and Kyun-Seop Bae. Gut and Liver 2023;17:92-9. https://doi.org/10.5009/gnl220050

27 June 2023 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MOMinkyung Oh
Minkyung Oh
HLHeechan Lee
Heechan Lee
SKSeokuee Kim
Seokuee Kim
BKBongtae Kim
Bongtae Kim
GSGeun Seog Song
Geun Seog Song
JGJong-Lyul Ghim
Jong-Lyul Ghim
Oh M, et al. Transl Clin Pharmacol. 2023 Jun;31(2):114-123. https://doi.org/10.12793/tcp.2023.31.e11

1 May 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JGJong-Lyul Ghim
Jong-Lyul Ghim
NPNguyen Thi Thu Phuong
Nguyen Thi Thu Phuong
MKMin Jung Kim
Min Jung Kim
EKEun-Ji Kim
Eun-Ji Kim
GSGeun Seog Song
Geun Seog Song
EKEun-Young Kim
Eun-Young Kim
Purpose: The aims of this study was to investigate the mutual pharmacokinetic interactions between steady-state atorvastatin and metformin and the effect of food on the fixed-dose combined (FDC) tablet of atorvastatin and metformin extended release (XR). Subjects and methods: Study 1, an open-labeled, fixed sequence, multiple-dose pharmacokinetic drug-drug interaction study, was divided into 2 parts. Atorvastatin (40 mg) or metformin (1,000 mg) XR tablets were administered once daily via mono- or co-therapy for 7 days. Plasma levels of atorvastatin and 2-OH-atorvastatin, were quantitatively determined for 36 h in part A (n=50) while metformin plasma concentration was measured up to 24 h in part B (n=16) after the last dosing. Study 2, a randomized, open-labeled, single-dose, two-treatment, two-period, two-sequence crossover study, involved 27 healthy subjects to investigate the impact of food intake on the pharmacokinetics of a combined atorvastatin/metformin XR 20/500 mg (CJ-30056 20/500 mg) tablet. Results: After multiple doses of mono- or co-therapy of atorvastatin (40 mg) and metformin (1,000 mg) XR, the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for the peak plasma concentration at steady state (Cmax,ss) and area under the plasma concentration–time curve during the dosing interval at steady state (AUCτ,ss) were 1.07 (0.94–1.22) and 1.05 (0.99–1.10) for atorvastatin, 1.06 (0.96–1.16) and 1.16 (1.10–1.21) for 2-OH-atorvastatin, and 1.00 (0.86–1.18) and 0.99 (0.87–1.13) for metformin, respectively. Food delayed time to reach maximum concentration (tmax), decreased atorvastatin Cmax by 32% with a GMR (90% CI) of 0.68 (0.59–0.78), and increased metformin AUCt by 56% with a GMR (90% CI) of 1.56 (1.43–1.69). Conclusion: No clinically relevant pharmacokinetic interaction was seen when atorvastatin was co-administered with metformin. Food appeared to change the absorption of atorvastatin and metformin from an FDC formulation. These alterations were in accordance with those described with the single reference drugs when ingested with food.

1 November 2014 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
HKHo-Sook Kim
Ho-Sook Kim
MOMinkyung Oh
Minkyung Oh
EKEun Ji Kim
Eun Ji Kim
GSGeun Seog Song
Geun Seog Song
JGJong-Lyul Ghim
Jong-Lyul Ghim
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
The objective of this study was to evaluate the effects of voglibose on the pharmacokinetics of metformin. A randomized, open-label, two-way crossover study with a 7-day washout period was conducted. All subjects were given an oral dose of metformin with or without voglibose 3 x daily for 7 days. Plasma concentrations of metformin on day 7 were measured using high performance liquid chromatography (HPLC) with UV detection for pharmacokinetic assessment Vital signs and adverse events were monitored, and physical examinations and laboratory tests were conducted to evaluate safety. 22 subjects completed the study. The geometric mean ratios for C(ss,max) of metformin (metformin plus voglibose vs. metformin only) were 0.98 (90% CI, 0.92 - 1.05; p > 0.05) and for AUC-τ, the ratio was 0.99 (90% CI, 0.92 - 1.06; p > 0.05). There were no significant differences in adverse drug reactions between metformin with and without voglibose. However, the incidence of adverse events was higher in period 1 than in period 2 (16 cases vs. 1 case, p < 0.001). Co-administration of metformin and voglibose had no statistically or clinically significant effects on the pharmacokinetics of metformin in healthy subjects. The pharmacodynamic interaction study to evaluate the effect of metformin on the pharmacodynamics of voglibose is in progress.